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Introduction: Levetiracetam (LEV) is a recently marketed novel anti-epileptic drug with a promising efficacy and safety profile.
In this report we describe two patients who presented with enterocolitis and discuss the possible relationship with concurrent
LEV intake.
Patients: In two patients, LEV was initiated to control refractory complex partial seizures (CPS). The first patient was treated
with 1500 mg/day and complained of abdominal pain and weight loss 6 months later. Internal examination and colonoscopy
revealed a punctate colitis. The second patient presented with bloody stool 1 month after LEV initiation. Colonoscopy showed
punctate colitis. In both patients gastrointestinal symptoms disappeared following tapering of LEV.
Discussion: There are no reports in the literature describing colitis related to LEV intake. Three possible mechanisms of action
are discussed. Colitis may be part of a hypersensitivity syndrome caused by LEV. Pharmacodynamic interactions with other
anti-epileptic drugs, for example, carbamazepine may play a role. A haematological adverse event is another possibility since
piracetam, a related molecule, has a known impact on erythrocytes and platelets.
Conclusion: The close temporal relationship between initiation of LEV intake, symptomatic colitis and clinical improvement
following LEV tapering, suggests that colitis may be a possible and previously undescribed adverse effect of LEV.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
Epilepsy is the second most common chronic neuro-
logical condition after migraine, affecting between 0.5
and 2% of the population.1 Medical treatment with
one or more first-line antiepileptic drugs (AEDs) will
render a majority of patients seizure free.2 However,
a recent 3-year study estimated that 44% of patients
with epilepsy fail to achieve seizure freedom, even
with medication.3 This high number emphasizes the
need for additional research and progress in epilepsy
treatment. Contemporary treatment options for these
patients include continued polytherapy with or with-
out novel AEDs, epilepsy surgery, or vagus nerve
stimulation.
Recently, several novel AEDs have been added to the
pharmacotherapeutic armamentarium.4,5 One of these
drugs is levetiracetam (UCB L059, “Keppra”, LEV),
a derivative of the nootropic drug piracetam6,7 with
a wide spectrum of anticonvulsant effects in animal
models for different types of epileptic seizures.8–12
Although the mechanism of action has not been fully
elucidated, the drug does not appear to act at any rec-
ognized site of AED activity such as GABA-receptors
or sodium channels.13 Instead, in vitro studies suggest
a specific binding site in the CNS membranes.14 Apart
from its antiepileptic effect there is evidence that LEV
may also exhibit antiepileptogenic properties.15
LEV also has a favorable pharmacokinetic profile.
In humans, LEV is rapidly and completely absorbed
after oral administration; there is no effect of food
intake on the extent of absorption. Peak LEV serum
concentrations occur approximately 1 h after admin-
istration in healthy young volunteers. Unlike some
other AEDs, LEV is not metabolized in the liver;
instead, it is transformed by enzymatic hydrolysis of
1059–1311/$30.00 © 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Enterocolitis: an adverse event in refractory epilepsy patients 77
the acetamide group in the blood to inactive metabo-
lites. LEV and its major metabolite are renally elim-
inated, with approximately 66% of a dose excreted
unchanged. Both compounds circulate largely un-
bound (<10% bound) to plasma proteins. The half-life
of 6–8 h in adults permits twice-daily dosing.4,16,17
In December 1999, the Food and Drug Administra-
tion (FDA) approved LEV for adjunctive therapy in
the treatment of partial-onset seizures in adults with
epilepsy.
LEV initiated at doses of 2000 or 4000 mg daily
without titration is well tolerated and effective as add-
on therapy in patients with partial and/or generalized
seizures.18 The most common side effects are asthe-
nia, dizziness, flu-like syndrome, headache, rhinitis
and somnolence.17 Number needed to treat analysis
shows that LEV belongs to the group of most effec-
tive AEDs.19 Recent literature suggests that LEV may
be even more effective for certain subpopulations, for
example, late-onset partial epilepsy20 and early after
failed epilepsy surgery.21
In Belgium, LEV became available for use in pa-
tients mid 2001. Patients taking one but no more than
two other AEDs and with at least one partial seizure
and no more than 14 partial seizures per month were
included in the Safety of Keppra as Adjunctive Ther-
apy in Epilepsy (SKATE) trial. For patients taking
more than two AEDs or with a higher seizure fre-
quency, LEV was made available by UCB Belgium in
compassionate use until reimbursement was granted
in July 2002.
Recently, a report speculated on a possible haemor-
rhagic diathesis in patients treated with LEV and un-
dergoing resective surgery for refractory epilepsy.22
Since 2001, 85 patients have been treated with LEV
as add-on therapy at the Reference Centre for Refrac-
tory Epilepsy in Ghent University Hospital, Belgium.
In 65 patients, comprehensive follow-up information
was available; the other 20 patients only recently re-
ceived LEV. Thirty patients out of 65 (46%) reported
one or more adverse events. Behavioural/emotional
problems (11 out of 65 patients, 17%) and asthe-
nia/somnolence (17 out of 65 patients, 26%) were the
most commonly reported individual adverse events.
One patient reported dizziness, one reported a nose
bleed, one female patient complained of menorrhagia
and three patients reported diplopia.
Here we describe two patients who presented with
abdominal symptoms while being treated with LEV
and discuss the possible relationships between this
side effect and exposure to LEV.
Worldwide, 140,674 patient years of LEV treatment
were reached in July 2002. At this time (January
2003), the number of patient years is estimated to have
reached 200,000. 150,000 patient years is accepted to
be the limit to reveal uncommon (exceptional) side
effects. Post-marketing studies have not reported any
uncommon side effects.
CASE-REPORT #1
JDL is a 63-year-old, right-handed woman with com-
plex partial epilepsy since 1993. At the age of 10, the
patient had a head trauma with a short-lasting loss of
consciousness. At age 36, she underwent a removal
of the uterus and ovaries because of suspected malig-
nancy. The patient suffered from migraine and also
had a history of two stomach ulcers, one complicated
with a bleeding that was conservatively treated, and
two tapeworm infections.
Habitual seizures occur typically after a migraine
attack and are followed by an episode of acute depres-
sion. Seizures are commonly preceded by an epigastric
aura followed by a reduced level of alertness, impaired
speech and ambulatory automatisms. Seizures often
occur in clusters of 1 day every month. Initially the pa-
tient was treated with carbamazepine and sodium val-
proate. Subsequent drug trials with newer AEDs such
as topiramate (200 mg daily) and lamotrigine (250 mg
daily) failed because of unacceptable side effects. Both
were discontinued because of pruritus and a rash.
The patient presented at the epilepsy clinic in
the Reference Centre for Refractory Epilepsy at
Ghent University Hospital in March 2000 and was
included in a presurgical evaluation protocol. Dur-
ing video-EEG monitoring, the patient had a flurry
of complex partial seizures (CPS) with clear-cut
temporal lobe semiology. The ictal EEG showed
left frontotemporal rhythmical theta recruitment at
the clinical onset. The interictal EEG showed left
frontotemporal spikes. Magnetic resonance imaging
(MRI) showed discrete bilateral hippocampal signal
changes on T2-weighted images. FDG-PET (positron
emission tomography) revealed a left frontotempo-
ral hypometabolism. Neuropsychological evaluation
revealed memory impairment suggestive of right tem-
poral involvement. Due to the bilateral abnormalities
on structural imaging, invasive video-EEG moni-
toring with bilateral depth electrodes was planned
following Wada-testing to assess language dominance
and memory performance. She failed the Wada-test,
possibly due to multiple seizures the night before and
refused to retake the test. Ultimately the patient chose
to halt further diagnostic procedures and to continue
with AED treatment.
At that time, her medication consisted of clon-
azepam (2 mg/day) and carbamazepine (800 mg/day).
She reported a seizure frequency of three to seven
CPS per month. Clinical investigations showed no
signs of drug intoxication. Tiagabine (30 mg/day)
was added to the AED regimen but had to be tapered
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shortly after initiation due to pruritus, stomach ache,
dizziness and headache. In February 2002, she was
included in the SKATE study and 1000 mg LEV was
added to her AED regimen. At the time of the second
follow-up consultation in April 2002, she was com-
pletely seizure-free but complained of tiredness and
depression. From a pre-study weight of 138 pounds,
she had lost 18 pounds over this period of 2 months.
There were no other associated systemic complaints at
this time and no signs of any drug toxicity on clinical
neurological examination and paraclinical investiga-
tions (RBC: 4.26× 106 l−1, Hg: 13.2 g/dl, platelets:
173× 103 l−1, gamma-GT: 34 U/l, CRP 1.7 mg/dl).
Sertraline was added to her medication regimen and
LEV was reduced to a dosage of 500 mg/day. After
being seizure-free for more than 15 weeks with LEV
treatment, she described a new cluster of seizures at
the consultation in May 2002. The dose of LEV was
increased to 1000 mg daily.
In August 2002, she reported five short-lasting CPS
over a period of 4 months. Here-upon, the dose of
LEV was increased further to 1500 mg daily. Be-
cause of fatigue, clonazepam was discontinued. She
also reported stomach ache and continuing weight
loss despite a good appetite in the previous weeks.
The patient was referred to the Gastro-enterology de-
partment. She complained of pain that was localized
in the right hypochondrium, spreading to the entire
upper abdomen and increasing after a meal. During
the last week she had experienced minor constipa-
tion. Stool had a normal colour and consistency and
no macroscopic blood involvement. Clinical exami-
nation displayed a non-tender abdomen with normal
bowel sounds. Blood pressure was 140/90 mmHg and
pulse rate was regular at 60 beats/min. There was a
normal palpation of breasts and thyroid. Laboratory
examination showed normal results (sedimentation
rate 1◦ per hour: 1 mm/unit, RBC: 4.29 × 106 l−1,
Hg: 13.4 g/dl, platelets: 198 × 103 l−1, gamma-GT:
42 U/l). Other liver function tests (LFT) including
PTT, glucose level and thyroid tests were normal
except for a slightly increased infectious parameter
(CRP: 0.7 mg/dl). Abdominal CT scanning showed
hypodense regions in the liver compatible with be-
nign cysts. There was no evidence for atherosclerotic
disease of the abdominal vessels. Gastroscopy yielded
normal findings. Colonoscopy revealed a punctate
colitis at the level of the ileocaecal region. Several
biopsy specimens had a histologically normal aspect.
In particular, no eosinophylic infiltrates could be
found.
After a reduction of the dosage of LEV, symptoms
immediately disappeared and did not re-occur. The
patient is currently (January 2003) on 1000 mg and has
reported the occurrence one CPS during the previous
3 months.
CASE-REPORT #2
WDS is a 32-year-old, heterosexual male with sim-
ple and CPS and sporadic secondary convulsions
since the age of 18, secondary to herpes encephali-
tis. Seizures typically occur in clusters of five to six
seizures in 2 days alternating with periods of relative
seizure freedom.
The patient underwent a comprehensive presurgi-
cal evaluation at Ghent University Hospital in 1998.
All performed examinations (video-EEG monitoring,
interictal FDG-PET, optimum NMR, neuropsycho-
logical testing and invasive EEG studies) suggested
right-sided medial temporal lobe seizure onset. Ac-
cordingly, a right temporal lobectomy and hippocam-
pectomy was performed in May 1999. One year after
surgery, he had a seizure frequency reduction of more
than 90%. He still experienced some short-lasting
episodes of staring, salivation and severe dizziness.
LEV (1000 mg/day) was added in February 2002 to the
AED regimen of carbamazepine 800 mg, sodium val-
proate 1500 mg and clonazepam 2 mg. The dosage of
LEV was increased with increments of 500 mg/week.
At this time, laboratory test values (blood chemistry,
haematology, glucose, lipids, hormones, drug mon-
itoring and enzymes) were completely normal apart
from elevated lipids (total cholesterol 246 mg/dl, TG
388 mg/dl) and gamma-GT (130 IU/l).
In May 2002, he reported five short-lasting episodes
of dizziness. He also complained of a bloody stool
during 1 week for which he received medication from
his general practitioner intended for haemorrhoids. At
the time of the next consultation, in September 2002,
he described two generalized epileptic seizures, re-
occurring episodes of bloody stool with no apparent
triggering factors and fatigue. Laboratory tests at that
time were normal (RBC: 5.16 × 106 l−1, platelets:
196×103 l−1, normal LFT including PTT, therapeu-
tic carbamazepine level: 7.6g/l, subtherapeutic val-
proate level: 40.4g/l and slightly elevated creatinine
concentrations: 1.10). The patient denied the intake of
antibiotics, NSAIDs or salicylic acids, and no enemas
were performed. Gastro-enterological examination re-
vealed a normal clinical status with a non-tender ab-
domen and normal bowel movements. Proctological
examination was negative and a colonoscopy was per-
formed which revealed a punctate colitis. Six biopsy
samples were histologically normal. No specific infil-
trates were found.
Because of the reoccurring episodes of bloody stool
and associated somnolence, LEV was discontinued.
At the latest follow-up consultation in October 2002
he reported no further change in seizure control and
no more generalized tonic–clonic insults. There was a
complete disappearance of the bloody stool after LEV
termination.
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DISCUSSION
Results of pre-clinical studies provide no evidence
for a carcinogenic, mutagenic, or teratogenic po-
tential of LEV.12 Cereghino et al. studied patients
with uncontrolled partial seizures in a double-blind,
randomised clinical trial. Of 199 patients receiving
LEV, treatment-emergent adverse events with an inci-
dence higher than placebo were: asthenia, dizziness,
flu syndrome, headache, infection, rhinitis and som-
nolence. 5.1% of patients reported abdominal pain
versus 10.5% in the placebo group.17 In another
European multi-centre, double-blind, randomised,
placebo-controlled trial in which add-on LEV therapy
was compared to placebo in 324 epilepsy patients,
the most frequent adverse events were similar: as-
thenia, headache, accidental injury and somnolence.
No clinically relevant changes compared to base-
line values were found for any monitored parameter
(blood chemistry, haematology, urine analysis, vi-
tal sings, ECG). Abdominal pain was reported in
5.7% of the patients receiving LEV 1000 mg/day
versus 3.6% in the placebo group.23 A recent review
including 3347 patients exposed to LEV summa-
rized that LEV is well tolerated and safe and that
the overall incidence of adverse effects in the LEV
groups was only slightly higher than in the placebo
groups.24
In view of the close temporal relation in our patients
between the start of LEV intake and the development
of colitis and the improvement after discontinuation,
an association seems not unlikely. Different mecha-
nisms of action could be implicated.
A first possibility is the occurrence of a hyper-
sensitivity syndrome, as described previously with
other AEDs. This entity is characterized by fever,
skin rash and involvement of multiple organ systems.
The pathogenic mechanisms responsible for the de-
velopment of hypersensitivity reactions are thought
to include genetically determined abnormalities in
enzymatic systems critical for the detoxification of
metabolites of aromatic AEDs.25,26 Colitis may be
part of this AED-related hypersensitivity syndrome.27
Because of the lack of other suggestive symptoms
besides colitis this hypersensitivity syndrome is not
the most likely explanation.
Due to the specific pharmacokinetic profile of LEV,
the risk of drug interactions is very low. The major
metabolic pathway is not dependent on the hepatic
cytochrome P450 system and LEV does not inhibit or
induce hepatic enzymes to produce clinically relevant
interactions. It is not appreciably protein-bound nor
does it affect the protein binding of other drugs. Thus,
because of its minimal protein binding and lack of
hepatic metabolism, the risk of drug pharmacokinetic
drug interaction is very low.16,28–31
Another hypothesis may be that the association
of carbamazepine with LEV could be the under-
lying cause. Earlier case reports have illustrated a
drug-induced enterocolitis caused by carbamaze-
pine.32,33 In a recent article, Sisodiya et al. describes
four patients with severe refractory epilepsy in whom
introduction of LEV led to disabling symptoms com-
patible with carbamazepine toxicity requiring either
carbamazepine dose reduction or LEV withdrawal.
As carbamazepine and carbamazepine-epoxide blood
levels were not altered during LEV co-medication,
a pharmacodynamic interaction was suggested.34
Adding lamotrigine to carbamazepine can also in-
crease carbamazepine-related side effect without
changes in carbamazepine or epoxide blood levels.35
While a mild presentation of carbamazepine-induced
colitis is not completely excluded in our patients,
their symptoms subsided when the dose of LEV was
tapered and the dose of carbamazepine remained
unchanged, making this an unlikely hypothesis.
Finally, especially in view of the bloody stool re-
ported in the second case report, haematological con-
siderations have to be taken into account. In the past,
the relationship between haematological side effects
and treatment with various AEDs has been made.36
For instance, valproate can cause direct bone marrow
suppression leading to aplastic anaemia or peripheral
cytopenia affecting one or more cell lines. A reported
bleeding diathesis associated with valproate use may
include thrombocytopenia, abnormal platelet function,
and acquired von Willebrand disease type I.37–39 Also
felbamate, phenytoin and carbamazepine occasionally
cause serious haematological disorders.40–42
Recently a case has been reported of a possible
increased diathesis in patients undergoing resective
surgery for refractory epilepsy who were treated with
LEV.22 The authors suggested that LEV treatment
could be associated with haemorrhagic complications
of epilepsy surgery more frequently than expected.
They also hypothesized that LEV may have a sub-
tle effect on megakaryocytes, producing a previously
unappreciated bleeding diathesis.22 Another recently
published case report described a worsening of an
immune thrombocytopenia during monotherapy with
LEV.43
Both piracetam and LEV are pyrrolidone derivatives
that share similar chemical structures but have distinct
pharmacological profiles and consequently different
clinical uses.6 Piracetam is known to have important
haemorrheological and antithrombotic properties that
are very useful in the treatment of stroke. It increases
the deformability of the erythrocyte membrane and de-
creases platelet aggregation in patients with increased
platelet aggregability,44–46 for example, in sickle cell
anaemia. Although not demonstrated in the literature
previously, it is therefore not unlikely that LEV may
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have some impact on erythrocytes or platelets and their
precursors, and exert haematological adverse events
via this mechanism. In the present cases, there is how-
ever no clear-cut evidence to consider an underlying
haematological aetiology for the punctate colitis.
Despite extensive experimental and clinical inves-
tigations concerning descriptions of the antiepileptic
action of LEV, the exact mechanism of its action is
still unknown. The existing experimental data do not
allow attribution to any of the three main mechanisms
currently accepted for the established AEDs: conven-
tional GABA-ergic facilitation or inhibition of either
Na+ or low-voltage-activated Ca2+ currents. Recently,
a study provided evidence that LEV selectively in-
hibits N-type calcium channel of pyramidal hippocam-
pal neurons, suggesting the evidence of a subtype of
N-type channels sensitive to LEV, possibly involved
in its antiepileptic action.47 Further elucidation of its
mechanism of action may also shed more light on its
side effect profile.
CONCLUSION
In view of the close temporal relationship between
LEV intake and development of colitis, the improve-
ment after discontinuation of LEV, and despite the
fact that only a control colonoscopy could prove the
regression of colitis, these case-reports suggest that
colitis may be a possible and previously undescribed
adverse effect of LEV.
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